Lipocine Inc (LPCN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Lipocine Inc (LPCN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8042
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Lipocine Inc (Lipocine) is a pharmaceutical company that develops and commercializes treatment for men’s and women’s health. The company’s pipeline products for men’s health include LPCN 1111 and LPCN 1021; and for women’s health include LPCN 1107. Its LPCN 1111 is an oral testosterone product candidate and LPCN 1021 is an oral testosterone replacement therapy with positive topline. Lipocine offers LPCN 1107, an oral hydroxyprogesterone caproate product for prevention of preterm birth. The company develops patented technology based on lipidic compositions that form optimal dispersed phase in the gastrointestinal environment for improved absorption of the insoluble drug. Its Lip’ral is a technology based on lipidic compositions that form optimal dispersed phase in the gastrointestinal environment. Lipocine is headquartered in Salt Lake City, Utah, the US.

Lipocine Inc (LPCN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lipocine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Lipocine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Lipocine Inc, Pharmaceuticals & Healthcare, Deal Details 11
Merger 11
Marathon Bar And Lipocine Complete Reverse Merger Transaction 11
Licensing Agreements 12
Lipocine Enters into Licensing Agreement with Spriaso 12
Equity Offering 13
Lipocine Plans to Raise up to USD10.8 Million in Public Offering of Shares 13
Lipocine to Raise USD20 Million in Public Offering of Shares 14
Lipocine Raises USD34.8 Million in Public Offering of Common Stock 15
Lipocine Completes Underwriters Exercise Of Full Over-Allotment Option Of Public Offering Of Shares For US$14.2 Million 17
Lipocine Completes Private Placement Of Shares For US$37.8 Million 18
Lipocine Inc – Key Competitors 19
Lipocine Inc – Key Employees 20
Lipocine Inc – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Aug 07, 2018: Lipocine announces financial and operational results for the second quarter and six months ended June 30, 2018 22
May 07, 2018: Lipocine Reported Financial and Operational Results for the First Quarter Ended March 31, 2018 24
Mar 12, 2018: Lipocine Reports Financial and Operational Results for the Fiscal Year Ended December 31, 2017 25
Nov 08, 2017: Lipocine Announces Financial and Operational Results for the Third Quarter and Nine Months Ended September 30, 2017 26
Aug 07, 2017: Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2017 27
May 08, 2017: Lipocine Announces Financial and Operational Results for the First Quarter 2017 29
Mar 06, 2017: Lipocine Announces Financial and Operational Results for the Full Year of 2016 30
Corporate Communications 31
Feb 15, 2017: Lipocine Announces the Promotion of Gregory Bass to Chief Commercial Officer 31
Legal and Regulatory 32
Feb 16, 2018: Lipocine Announces Settlement of Securities Class Action Lawsuit 32
Sep 21, 2017: Lipocine Announces Motions Decision by USPTO in Interference Against Clarus 33
Product News 34
06/19/2017: Lipocine to Host Conference Call and Webcast to Discuss Top-Line Results From the Dosing Validation and Dosing Flexibility Studies of LPCN 1021 34
06/19/2017: Lipocine Validates “No Titration”Dosing Regimen With Positive Topline Efficacy Results for LPCN 1021, Oral Testosterone Candidate 35
Product Approvals 36
May 09, 2018: Lipocine Receives Complete Response Letter for TLANDO From U.S. Food and Drug Administration 36
Jan 10, 2018: Lipocine Announces Outcome of FDA Advisory Committee Meeting for TLANDO, Testosterone Replacement Therapy in Adult Males with Hypogonadism 37
Nov 17, 2017: U.S. FDA Extends Review for TLANDO; Advisory Committee Meeting Date of January 10, 2018 Remains Unchanged 38
Oct 18, 2017: FDA Advisory Committee Scheduled to Review TLANDO on January 10, 2018 39
Sep 20, 2017: Lipocine Announces FDA Advisory Committee Meeting for TLANDO 40
Aug 14, 2017: Lipocine Announces FDA Acknowledgement of TLANDO (“LPCN 1021”) NDA Resubmission; PDUFA Goal Date, February 8, 2018 41
Aug 09, 2017: Lipocine Resubmits NDA for Its Oral Testosterone Product Candidate, LPCN 1021, for Treatment of Hypogonadism 42
Clinical Trials 43
Jun 07, 2018: Lipocine Announces Dosing in Ambulatory Blood Pressure Study for TLANDO 43
Apr 24, 2017: Lipocine Completes Enrollment in the LPCN 1021 Fixed Dose Clinical Trials 44
Jan 05, 2017: Lipocine Initiates a Dosing Flexibility Study for LPCN 1021, Its Oral Testosterone Replacement Product Candidate 45
Other Significant Developments 46
Feb 08, 2018: Lipocine Announces $10 Million Loan and Security Agreement with Silicon Valley Bank 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Lipocine Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lipocine Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lipocine Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Lipocine Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Marathon Bar And Lipocine Complete Reverse Merger Transaction 11
Lipocine Enters into Licensing Agreement with Spriaso 12
Lipocine Plans to Raise up to USD10.8 Million in Public Offering of Shares 13
Lipocine to Raise USD20 Million in Public Offering of Shares 14
Lipocine Raises USD34.8 Million in Public Offering of Common Stock 15
Lipocine Completes Underwriters Exercise Of Full Over-Allotment Option Of Public Offering Of Shares For US$14.2 Million 17
Lipocine Completes Private Placement Of Shares For US$37.8 Million 18
Lipocine Inc, Key Competitors 19
Lipocine Inc, Key Employees 20
Lipocine Inc, Other Locations 21

List of Figures
Lipocine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Lipocine Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Lipocine Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Lipocine Inc (LPCN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Precision System Science Co Ltd (7707):医療機器:M&Aディール及び事業提携情報
    Summary Precision System Science Co Ltd (PSS) is a medical device company that develops, manufactures and sells automated systems, physicochemical instruments, software, and others. The company provide products such as automated nucleic acid isolation system, large sample volume nucleic acid extract …
  • Meera Industries Ltd (540519):企業の財務・戦略的SWOT分析
    Meera Industries Ltd (540519) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • High Peak Royalties Limited (HPR)-エネルギー分野:企業M&A・提携分析
    Summary High Peak Royalties Limited (High Peak) is a utility company that builds a portfolio of diversified resource royalties with projects in exploration, pre-production and producing phases. It assesses a regular flow of potential royalty investments across the resources sector. The company has r …
  • ESI Group S.A. (ESI):企業の財務・戦略的SWOT分析
    ESI Group S.A. (ESI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Lazard Ltd:戦略・SWOT・企業財務分析
    Lazard Ltd - Strategy, SWOT and Corporate Finance Report Summary Lazard Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Scientex Bhd (SCIENTX):企業の財務・戦略的SWOT分析
    Summary Scientex Bhd (Scientex) is a manufacturer and supplier of packaging products and component parts for automotive interior. The company operates through stretch and custom film, converting, specialty products and property development divisions. It offers lamination base, general, barrier and a …
  • DPR Construction Inc:企業の戦略的SWOT分析
    DPR Construction Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Swagelok Company:企業の戦略・SWOT・財務情報
    Swagelok Company - Strategy, SWOT and Corporate Finance Report Summary Swagelok Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Dottikon ES Holding AG (DESN):企業の財務・戦略的SWOT分析
    Dottikon ES Holding AG (DESN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Terex Corporation:企業の戦略・SWOT・財務情報
    Terex Corporation - Strategy, SWOT and Corporate Finance Report Summary Terex Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Bankinter Banca Privada:企業の戦略・SWOT・財務情報
    Bankinter Banca Privada - Strategy, SWOT and Corporate Finance Report Summary Bankinter Banca Privada - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Alon USA Energy, Inc.:企業の戦略・SWOT・財務情報
    Alon USA Energy, Inc. - Strategy, SWOT and Corporate Finance Report Summary Alon USA Energy, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Trinity Industries Inc (TRN):企業の財務・戦略的SWOT分析
    Trinity Industries Inc (TRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • 3M Health Information Systems Inc:医療機器:M&Aディール及び事業提携情報
    Summary 3M Health Information Systems Inc (3M HIS), a subsidiary of 3M Co, is a software and consulting services provider. The company offers healthcare technology, software and consulting services. Its services are designed for clinical documentation improvement, computer-assisted coding, mobile ph …
  • Voith Hydro Holding GmbH & Co KG:企業の戦略的SWOT分析
    Voith Hydro Holding GmbH & Co KG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Karnataka Power Corporation Ltd-エネルギー分野:企業M&A・提携分析
    Summary Karnataka Power Corporation Limited (KPCL) is a state owned power generating company in Karnataka. It is responsible for development and operation of power plants including hydro, thermal, solar and wind. KPCL supplies power to state owned power distribution companies based on power purchase …
  • Curemark LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Curemark LLC (Curemark) is a biopharmaceutical company that develops novel therapies for the treatment of neurological disorders. The company’s pipeline products include CM-AT, CM-4612, CM-PK, CM-182, and CM-1212 drug candidates. Its drug candidate CM-AT is a clinical trial for autism, ADHD, …
  • Intuitive Surgical Inc (ISRG):企業の財務・戦略的SWOT分析
    Intuitive Surgical Inc (ISRG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • MILEI GmbH:戦略・SWOT・企業財務分析
    MILEI GmbH - Strategy, SWOT and Corporate Finance Report Summary MILEI GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Cogentix Medical Inc (CGNT):企業の財務・戦略的SWOT分析
    Summary Cogentix Medical Inc (Cogentix Medical), formerly Vision-Sciences Inc, is a medical device company that designs, develops, manufactures and markets fiberoptic and video endoscopy products. The company’s major products include PrimeSight endoscopy systems, Urgent PC neuromodulation system and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆